Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Lexicon Pharmaceuticals Stories

2014-01-20 12:23:08

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 Summary GBI Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes...

2014-01-13 23:05:06

Mice Model Market report categorizes the global mice model market into the following segments and sub-segments - By Type, By Technology, By Disease, By Service & Geography (PRWEB) January 13, 2014 This report studies “Mice Model Market - by Type [Inbred, Knockout, Conditioned], Technology [Microinjection, Embryonic Stem Cell], Disease [Oncology, Immunology, CNS], Service [Breeding, Cryopreservation, Quarantine] & Care Products [Cages, Bedding, Feed] - Forecasts to 2018”. The...

2014-01-13 08:26:10

New Phase in Company Evolution from Genetics to Therapies THE WOODLANDS, Texas, Jan. 13, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today it is focusing its resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, and preparation for the transition to commercialization. Lexicon will continue to meet its obligations to existing partners and expects to continue to...

2014-01-08 23:22:27

RnRMarketResearch.com adds “Mice Model Market – by Type [Inbred, Knockout, Conditioned], Technology [Microinjection, Embryonic Stem Cell], Disease [Oncology, Immunology, CNS], Service [Breeding, Cryopreservation, Quarantine] & Care Products [Cages, Bedding, Feed] – Forecasts to 2018” to its store. Dallas, Texas (PRWEB) January 08, 2014 Over the years, the mice model market, which includes models and services, has witnessed many innovations that have led to an increase in the...

2014-01-08 08:27:06

THE WOODLANDS, Texas, Jan. 8, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the J. P. Morgan Healthcare Conference on Wednesday, January 15, at 9:30 AM PST in San Francisco. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com....

2014-01-07 08:31:41

DALLAS, January 7, 2014 /PRNewswire/ -- This report studies "Mice Model Market - by Type [Inbred, Knockout, Conditioned], Technology [Microinjection, Embryonic Stem Cell], Disease [Oncology, Immunology, CNS], Service [Breeding, Cryopreservation, Quarantine] & Care Products [Cages, Bedding, Feed] - Forecasts to 2018". The market is estimated at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018....

2013-12-20 08:24:22

NEW YORK, December 20, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Dyax Corp. (NASDAQ: DYAX), IPC The Hospitalist Company, Inc. (NASDAQ: IPCM), Array BioPharma Inc. (NASDAQ: ARRY), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), and Wright Medical Group, Inc. (NASDAQ: WMGI). Today's readers may access these reports free of charge - including full...

2013-12-03 08:31:24

THE WOODLANDS, Texas, Dec. 3, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome. The primary endpoint of this...

2013-12-02 08:29:53

Thursday December 5, The Yale Club, 50 Vanderbilt Ave., New York, NY THE WOODLANDS, Texas, Dec. 2, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will hold its R&D Day on Thursday, December 5, 2013 from 9:00 a.m. to 12:00 p.m. Eastern Time at the Yale Club, 50 Vanderbilt Ave., in New York City. Members of Lexicon's senior management team will provide in-depth reviews of the company's drug development programs. The agenda will include a presentation by...

2013-11-15 08:26:46

THE WOODLANDS, Texas, Nov. 15, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies Global Healthcare Conference on Wednesday, November 20, at 1:40 PM GMT (8:40 AM ET) in London. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the...